These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20878117)

  • 41. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
    Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
    Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
    Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure.
    Qiu X; Rong X; Yang J; Lu Y
    BMC Ophthalmol; 2019 Feb; 19(1):42. PubMed ID: 30717701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models.
    Bracker TU; Sommer A; Fichtner I; Faus H; Haendler B; Hess-Stumpp H
    Int J Oncol; 2009 Oct; 35(4):909-20. PubMed ID: 19724929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
    Richon VM; Sandhoff TW; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.
    Shin S; Lee EM; Cha HJ; Bae S; Jung JH; Lee SM; Yoon Y; Lee H; Kim S; Kim H; Lee SJ; Park IC; Jin YW; An S
    Int J Oncol; 2009 Dec; 35(6):1343-52. PubMed ID: 19885557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Histone deacetylase inhibitor (HDACi) upregulates activin A and activates the Smad signaling pathway in melanomas.
    Lee J; Ko J; Yi JY
    J Dermatol Sci; 2018 Apr; 90(1):13-20. PubMed ID: 29290529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
    Qin Y; Zhao X; Fang Y
    Int J Gynecol Cancer; 2014 Oct; 24(8):1373-80. PubMed ID: 25188886
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA).
    Basu HS; Mahlum A; Mehraein-Ghomi F; Kegel SJ; Guo S; Peters NR; Wilding G
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):705-15. PubMed ID: 20512578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
    Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
    Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer.
    Finnegan E; Ding W; Ude Z; Terer S; McGivern T; Blümel AM; Kirwan G; Shao X; Genua F; Yin X; Kel A; Fattah S; Myer PA; Cryan SA; Prehn JHM; O'Connor DP; Brennan L; Yochum G; Marmion CJ; Das S
    Cell Oncol (Dordr); 2024 Apr; 47(2):533-553. PubMed ID: 37934338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
    Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
    Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
    Huang HL; Peng CY; Lai MJ; Chen CH; Lee HY; Wang JC; Liou JP; Pan SL; Teng CM
    Oncotarget; 2015 Mar; 6(7):4976-91. PubMed ID: 25669976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
    Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
    Cheng HT; Hung WC
    Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improvement of resistance to oxaliplatin by vorinostat in human colorectal cancer cells through inhibition of Nrf2 nuclear translocation.
    Tanaka S; Hosokawa M; Tatsumi A; Asaumi S; Imai R; Ogawara KI
    Biochem Biophys Res Commun; 2022 Jun; 607():9-14. PubMed ID: 35358872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
    Wei Y; Zhou F; Lin Z; Shi L; Huang A; Liu T; Yu D; Wu G
    Anticancer Drugs; 2018 Mar; 29(3):262-270. PubMed ID: 29356692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.